Found 47 articles
Cognito Therapeutics Receives FDA Breakthrough Device Designation for Next-Generation Digital Therapeutic in Alzheimer’s Disease
Cognito Therapeutics, a clinical-stage company leading the development of a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders, announced today its lead product has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the treatment of cognitive and functional symptoms associated with Alzheimer’s disease.
Cognito Therapeutics, a clinical-stage company leading the development of a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders including Alzheimer’s disease, announced today the appointment of industry veteran Brent Vaughan as Chief Executive Officer.
Biotech and pharma companies tap new members of executive leadership teams and boards.
Cognito Therapeutics is a clinical-stage medical device company developing non-invasive neurostimulation therapies for neurodegenerative disorders such as Alzheimer’s disease
Vectra research highlights precarious security risks in the healthcare industry due to legacy infrastructures and unmanaged devices
Recently published research by MIT neuroscientists indicates that amyloid plaques could be reduced via brain wave stimulation.